Current Advances in the Science of Osteosarcoma

This thoroughly revised second edition is an up-to-date overview of the new advances in the knowledge of the basic science in sarcoma and osteosarcoma. It features detailed, in-depth discussions of microRNAs in osteosarcoma, historical perspectives of chemotherapy in the treatment of the disease, tumor targeted IL12 therapy and HER2 targeted therapy, the role of enhancer elements in regulating the prometastatic transcriptional program and more. Further, this essential volume also includes new insights on Wnt signaling in osteosarcoma, the role of genomics, genetically modified T-cell therapy, liquid biopsy, oncolytic viruses, immunophenotyping, receptor tyrosine kinases and epigenetic-focused approaches for treatment of osteosarcoma metastases, as well as thoughts on the current standard of treatment for patients suffering from these cancers. In the years since the previous edition, there have been numerous new developments in this rapidly changing field; this new edition is both timely and urgently needed. When taken together these companion volumes, Current Clinical (Book 1) and Scientific (Book 2) Advances in Osteosarcoma, are a timely and urgently needed guide for laboratory investigators and clinical oncologists.

Autorentext

Eugenie S. Kleinerman, (Editor), holds the Mary V. and John A. Reilly Distinguished Chair, and is currently Professor at the University of Texas MD Anderson Cancer Center in the Departments of Pediatrics Research and Cancer Biology. Dr. Kleinerman is internationally recognized for her scientific and clinical expertise in sarcomas, particular osteosarcoma, and for pioneering the use of a unique immunotherapy agent, liposome-encapsulated MTP-PE, for patients with newly diagnosed osteosarcoma or unresponsive relapsed osteosarcoma lung metastases. Her current research interests include developing novel ways to treat sarcoma patients by identifying new therapeutic targets, the properties that influence metastases, the efficacy of dendritic cell vaccines with and without checkpoint inhibitors for osteosarcoma lung metastases, how tumor vessels are formed in Ewing sarcoma and the use of exercise interventions to mitigate chemotherapy-induced cardiotoxicity.

Richard Gorlick, (Co-Editor), is currently the Mosbacher Pediatrics Chair of the Department of Pediatrics Patient Care, and Division Head of Pediatrics at the University of Texas MD Anderson Cancer Center. Dr. Gorlick is an internationally recognized expert in pediatric oncology and hematology, whose research and clinical work have focused on sarcomas, tumors that grow in connective tissues including bones, muscles, tendons and cartilage, understanding the mechanisms behind the development and progression of osteosarcoma, as well as targeted therapies and new drugs for childhood cancers.

Inhalt

1The genomic complexity of osteosarcoma and its implication for preclinical and clinical targeted therapies

2Genomics and the Immune Landscape of Osteosarcoma

3RECQ DNA Helicases and Osteosarcoma

4Targeting the Cancer Epigenome with Histone Deacetylase Inhibitors in Osteosarcoma

5Oncolytic viruses and their potential as a therapeutic opportunity in Osteosarcoma

6Applying Osteosarcoma Immunology to Understand Disease Progression and Assess immunotherapeutic Response

7Targetable intercellular signaling pathways facilitate lung colonization in osteosarcoma

8Wnt Signaling in Osteosarcoma

9Receptor Tyrosine Kinases in Osteosarcoma: 2019 update

10The Role of ALDH in the Metastatic Potential of Osteosarcoma Cells and Potential ALDH Targets

11Autophagy in OS

12Fas signaling as a potential target for the treatment of osteosarcoma metastasis in the lungs

13Exosomes: Dynamic Mediators of Extracellular Communication in the Tumor Microenvironment

14Comparative Immunology and Immunotherapy of Canine Osteosarcoma Index